Day 0 – Symposium Day at ASH2018

Jack Aiello |

Friday, November 30, 2018 November 30th is actually the day before ASH officially begins, often called “Symposium” day. However, my first session was last night’s Bone Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup MRD and Immune Profiling Meeting, a group focused supporting myeloma clinical trials involving transplants and immunotherapies. There were probably 100 […]

Using Minimal Residual Disease (MRD) in Clinical Practice

Jim Omel |

Each year as ASH begins the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup meets to improve treatment approaches related to transplantation in multiple myeloma. This group, representing all significant transplantation centers, discussed incorporating minimal residual disease (MRD) testing to better serve patients. These are some of the questions they reviewed.   […]

The Things We Learn at ASH

Jim Omel |

I look forward every year to Annual ASH Meeting, whether I’m attending in person or experiencing it from home via Twitter, blogs, and professional writers. At ASH we learn new advances in treating, evaluating, and living with myeloma. Immunology has become a central focus of recent ASH meetings and #ASH18 #IMFASH18 will be more of […]